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Summary: Urinary carcino-embryonic antigen (CEA) was measured in a follow-up study of 101 bladder carcinoma
patients. Urinary CEA estimation during follow-up appears to be of clinical value. Negative results can be interpreted
only in relation to previously increased values. Positive results are of value in retrospect when combined with negative
data, e.g in evaluation of suspicious bladder changes afid as an early indication of renewed tumour growth. Increased
CEA levels in urines from patients with urinary infection'rapidly decline once the infection is cured.
Klinische Bedeutung des carcino-embryonalen Antigens, 3. Mitteilung
Bewertung der Bestimmung des carcino-embryonalen Antigens im Urin während der Verlaufskontrolle
bei Patienten mit Blasenkrebs.
Zusammenfassung: Bei 101 Patienten wurden die Konzentrationen des carcino-embryonalen Antigens (CEA) im Urin
im Vergleich mit den Therapie-Effekten bewertet. Hieraus ließ sich schließen, daß der CEA-Bestimmung in dieser
Hinsicht klinische Bedeutung beigemessen werden kann. Normale CEA-Werte können klinisch nur interpretiert
werden, wenn diese in Folge von vorher erhöhten Werten gefunden worden sind. Erhöhte Werte haben nur Aussage-
kraft im Zusammenhang mit früher gemessenen normalen Werten, z. B. in der Auswertung von verdächtigen Prozessen
in der Blase und als ein frühzeitiger Hinweis auf erneutes Tumorwachstum.
Introduction
Since 1972 several authors (1^6) have shown that
increased urinary CEA1) levels can occur in association
with bladder carcinoma.
In a previous paper (6) we studied urinary CEA levels
in several groups of subjects with and without bladder
carcinoma. We tried to correlate several parameters of
the bladder tumour with urinary CEA levels. In addition,
efforts were made to gain better insight into the origin
of urinary CEA. It was concluded that the assay of
CEA in urine is helpful in detecting a tumour mass in
the bladder.
In this paper we try to evaluate whether measurement
of urinary CEA can be clinically helpful during follöw-üp
of patients with bladder carcinoma or previous bladder
carcinoma.
*) Abbreviation: CEA = carcino-embryonic antigen.
Materials and Methods
Unless stated otherwise urines were collected during cystoscopy.
A culture was made of a part of each sample. Another part of the
sample was dialysed, using cellulose acetate tubing for 4 hours
against phosphate-buffered saline (50 mmol/1 phosphate;
0.1 mmol/1 K2EDTA; pH 7.4). The dialysed portions were
stored frozen until assay of CEA. Cultures of the urines were
grown on gel plates within a few hours of collection. Urinary
infection was considered to be present if more than 108
colonies/1 were found. CEA was measured in duplicate by the
procedure described in a previous paper. Assays were per-
formed in dialysed urines, undiluted as well as diluted 1:2
with phosphate-buffered saline (7). The upper limit of normal
urinary CEA is 30 Mg/1 (6).
Patients
In 101 patients, 82 male and 19 female, who suffered or had
previously suffered from bladder carcinoma, CEA levels were
measured several times during follow-up. The patients were
aged between 28 and 87 years, The tumours were classified
and staged according to the UICC criteria (8). Unless stated
otherwise, the patients were free of urinary infection at the
time of urine collection. In all cases urinary CEA was estimated
without knowledge of the clinical status of the subject involved.
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The diagnosis was made and treatment given without reference
to the CEA values. Results of treatment were assessed and
recorded independently of the results of the CEA assays.
Results
According to their CEA pattern the patients were divided
into 4 groups.
1. Patients whose urinary CEA was and remained normal
This group comprises 70 patients:
a. 63 patients, showing normal CEA levels on several
occasions, were tumour-free whenever urinary
CEA was measured. Some showed papillomas, i.e.
non-invasive bladder carcinoma or a radiation ulcus
in the bladder on some occasions of urine collection.
b. One patient had a normal CEA level in urine on
two different occasions at ah interval of two
months. However, no tumour was found in the
bladder the first time, the second time a tumour
had grown.
c. In 6 patients CEA in urine was normal on several
occasions. At .the onset Of the period studied, a
bladder tumour was found in these patients. Later
results corresponded to tumour-free situations
(after therapy).
2. Patients who showed a rise of urinary CEA level
during follow-up after an initial normal value
This group consists of 10 patients:
a. 7 patients with initial normal CEA levels were found
to be free from tumours. In the course of time in-
creased CEA levels occurred. Clinical data revealed
that these increased values corresponded with re-
growth of tumours.
b. In three patients CEA changed from normal to ele-
vated values during follow-up. These patients are
here described separately because tumour growth
could not be established with certainty at the time
of increased CEA values. In the first case CEA had
risen to a slightly positive value (32 Mg/1).
A bleeding spot was seen in the bladder, but
malignancy was not confirmed. After coagulation
CEA decreased to normal.
In the second case CEA rose to 52 Mg/l. At that
time the bladder showed a few dubious spots.
In the third case CEA excretion changed from .
negative to 60 μg/l. In this patient the mucosa of
the bladder showed changes apparently due to
previous irradiation, performed years ago, but no
tumour was found.
3. Patients with increased urinary CEAt decreasing to
normal levels
This group comprises 15 patients.
a. In 9 patients a tumour was observed in the bladder
at the time of the initial increased CEA levels.
During follow- p (after treatment) normal CEA
amounts were measured and the tumour mass had
disappeared.
b. In three patients with high urinary CEA levels the
bladder contained a tumour, but an infection of
the urinary tract was also present. Subsequent CEA
measurements showed normal values in each case
and in each patient tumour and urinary infection
had disappeared.
c. With a view to the course of the urinary CEA
during and after urinary infection, three patients
with urinary infection but without bladder tumour
were studied. It is to be noted that these patients had
previously had a bladder carcinoma. The CEA levels
were > 300 Mg/1, 260 /zg/1 and 72 μ%1\. Ten, 6 and
1 */2 months later, respectively, CEA was measured
again and found to be normal. The urinary infection
had disappeared.
4. Patients with persistently increased urinary CEA levels
This group includes 6 patients:
a. In one patient without urinary infection an in-
creased CEA concentration was found twice (88
and 200 μ§/1, respectively), at an interval of
12 months. At both CEA measurements the bladder
contained a tumour. It is of interest to note that
intercurrent examination after treatment dis-
closed that the bladder was tumour-free. At that
time no CEA assay was made.
b. One patient showed a high CEA level in the urine,
and cystoscopy revealed a tumour in the bladder.
The patient was treated by irradiation, resulting in
subjective improvement for 7 months. Estimations
performed in urine collected 9l/2 and 12*/2 months
later, respectively, showed decreased but still
elevated levels. At the former time necrotic tumour
tissue was observed in the bladder. Unfortunately,
the result of the urinary culture is unknown. Clinical
examination three months later revealed renewed
tumour growth in the bladder. Urinary infection
was 'absent.
c. In one patient without urinary infection an in-
creased CEA level was found twice (51 μg/l and
45 μζϋ, respectively) at an interval of 5 months.
Prior to the first measurements there had been a
period (8 months) of subjective improvement after
irradiation, except for the last 7 weeks. A bleeding
vessel was found in the bladder at the time of the
first CEA measurement. A month later a tumour
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mass was observed in the bladder. The same was
observed at the second CEA measurement.
d. In one patient there was evidence that both urinary
infection and bladder tumour were present. The
urinary CEA level was 105 #g/l. A few weeks later
the CEA was still increased (85 μ§/1). Examination
revealed that a bladder tumour was present and
that the urinary infection had been cured.
e. In two other patients CEA was elevated while a
urinary infection was present, but no tumour was
found in the bladder. La;ter, the CEA was still in-
creased, but the urinary infection had been cured.
However, at that time the bladder still contained
a tumour.
Case histories
A few case histories will serve to illustrate the above data.
Case no. 1. Patient v. E. (fig. la), a 63-year-old man, who had
been irradiated 2 years earlier for a bladder carcinoma, stage
T4, had a radiation ulcus in the bladder at the first CEA
measurement (< 30 Mg/1). Five months later an increased
urinary CEA was observed (38 μg/l, midstream urine). Unfor-
tunately no cytoscopic data were available. Two weeks later,
urinary CEA was 71 Mg/1 and at that time cystoscopy revealed
a tumour with a diameter of 3-5 cm.
Case no. 2 (fig. 1 b) depicts the course of urinary CEA levels in
patient S., a woman aged 63, whose bladder tumour (stage T2)
had been surgically removed a month before the onset of the
period. At the first CEA measurement (< 30 Mg/1) she had an
ulcus in the bladder. A few months later excretion of urinary
CEA had increased to 49 Mg/1. At that time a tumour with a
diameter of 1 cm was found in the bladder. Irradiation resulted
in disappearance of the tumour and subsequent CEA estimation
gave a normal result.
Case no. 3 (fig. 1 c) describes patient J., a man aged 63. Irradia-
tion of the bladder tumour (stage T4) had been performed
8 months before. At the time indicated by the onset of the
period shown in the figure; CEA in the urine was normal.
Cystoscopy failed to reveal the presence of a tumour.
The same observations were repeated five months later. How-
ever, 5 months after the second measurement CEA in the
urine had increased to 177 Mg/1. At that time the bladder con-
tained a tumour and the patient also had a cystitis. Four months
later the urinary CEA concentration was 54 Mg/1. The tumour
was still present, but the cystitis had disappeared.
Case no. 4 refers to patient d. V., a man aged 58, who had been
irradiated for bladder carcinoma (stage T3) 5 years before the
onset of the perio4 illustrated in figure 1 d. At the times of the
first and second CEA measurements the bladder was found to
be free of tumour. A year later, CEA was elevated and at that
time a bleeding tumour with a diameter of 2^3 cm was ob-
served.
Case no. 5 refers to patient HL a 67-year-old man, whose bladder
carcinoma had been diagnosed and treated elsewhere 2 years
before the first CEA measurement, shown in figure 2 a. About
a month before the time of the assay the diagnosis was re-
confirmed and the tumour classified as T4. At the time of the
first CEA estimation (46 Mg/1) the bladder contained a tumour
with a diameter > 5 cm. Immediately after this measurement
irradiation was started. During irradiation CEA was measured
twice (45 and 98 Mg/1, respectively). The bladder was not
examined for tumour. Seven months later urinary CEA was
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Fig. 1. Variation with time of urinary CEA.
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Fig. 2. Variation with time of urinary CEA.
The sign >-* denotes period of irradiation. See also text.
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Case no. 6. Patient v. B. (fig. 2b), a 58-year-old man, excreted
155 Mg/1 CEA. The diameter of the tumour was > 5 cm (stage
T3). During irradiation, while the tumour was still present, CEA
had decreased to 55 i/g/l. Two months later, while CEA was
81 Mg/1, the bladder contained necrotic tumour tissue. Three
months later CEA had decreased to normal. The bladder was
found to be free from tumour at that time.
Case no. 7. Patient F. (fig. 2c), a 62-year-old man, suffering from
a bladder tumour with a diameter > 5 cm (stage TS), excreted
45 Mg/1 CEA in urine. Four months later, after irradiation, the
tumour had disappeared. The bladder contained a few papillomas
and CEA in urine was normal. Four months after this measure-
ment CEA had increased to 35 /ig/1; the bladder showed no
rumour. A month later some bleeding vessels in the bladder had
to be coagulated. Again 4 months later, CEA was normal and
the bladder showed a small papilloma.
Case no. 8. Patient B., a man aged 59, is illustrated in figure 2d
At the time of the first CEA measurement (87 Mg/1) a tumour
(stage T4) with a diameter of 12 cm was found in the bladder.
Six months later after irradiation, cystoscopy showed a small
amount of residual necrotic tumour tissue. Urinary CEA was
normal. About 3 months later the bladder still contained
some tumour. At this time the patient's history suggested, that
renewed tumour growth might be present. CEA was slightly
increased (32 Mg/1). The tumour was coagulated. Later CEA
results, after 4 and 10 months, respectively, were within the
normal range. The bladder was free from tumour.
Discussion
This is the first published study on the serial estimation
of urinary CEA levels in relation to the clinical situation
during a follow-up on bladder carcinoma. In a previous
report (6) it was stated that false-negative results (i.e
CEA values ̂  30 §/1) can be found in the presence of
a bladder tumour. This phenomenom was also observed
in this study (Results, 1 b and 1 c).
Consequently a single negative result of a CEA assay in
urine does not add essential information on the patient's
clinical condition. From the results of this study it
appears, however, that negative results do have a value
if they follow previously estimated positive values. They
indicate successful therapy of the bladder carcinoma.
Initial negative results may also be of value in retrospect,
if followed by increased CEA levels. In these cases an
elevated value indicates recurrence or reactivation of
tumour growth in the bladder (see Results, 2a). Let us
also consider in this respect figure 1 a, illustrating
detection of a bladder tumour by measurement of
urinary CEA, two weeks before cystoscopy. Cystoscopy
is regularly carried out during follow-ups on bladder
carcinoma. It seems to be important to estimate urinary
CEA levels several times between two cystoscopies. In
a number of cases this may lead to earlier discovery of
recurrence of the bladder tumour.
Positive data in this study were nearly always related to
tumour growth in the bladder once urinary infection was
excluded. A few cases in which this relation is not so
obvious merit some attention. In one patient we found a
slightly elevated CEA value, but no tumour mass or any
other change in the bladder (fig. 2c). A month later
some bleeding vessels in the bladder had to be coagulated,
which possibly indicated tumour growth in the bladder;
this could explain the intermediate CEA rise. In a few
cases increased urinary CEA was related to suspicious
lesions in the bladder (Results, 2b and 4c).
It seems justifiable to assume that the increased urinary
CEA in the cases just mentioned reflects the presence of
a tumour. Additional support can be found in the data
on the patient described under Results 4c, in whom a
tumour was observed a month after the finding of an
increased CEA. In another patient (Results, 2b third
case), no relation between increased urinary CEA level
and tumour presence was demonstrable. The only ab-
normality observed in the bladder of this patient was
a change in the mucosa due to irradiation.
A few results indicate (fig. 2 a and b) that disintegration
' of the tumour cells may probably cause a short rise of the
CEA level. An important complication in the interpreta-
tion of urinary CEA levels is the appearance of urinary
infection (1—6). The influence of infection on the results
is also clearly shown in Results (section 3b, 4d, 4e
and fig. 1 c). It is important to know how long the CEA
level remains increased after disappearance of a urinary
infection, äs measured by culture. The results (section
3c) suggest that elevation of CEA does not extend over
a long period. The data obtained shortly after a cured
infection can therefore be considered a rather reliable
aid in the diagnosis of bladder tumour. The question
arises in how many patients whose urinary CEA has
returned to normal after successful therapy, recurrence
of the tumour is reflected by a rise of urinary CEA. The
question is prompted by the fact that ä previous study
(6) revealed that 47 % of bladder carcinoma patients
have normal urinary CEA. Long-term follow-up studies
are required to answer this question. At this time we tend
to conclude that CEA levels which decrease from elevated
to normal or vice versa reflect progression or regression
of malignant processes in the bladder. The urinary CEA
assay can therefore be helpful in assessing adequacy of
treatment in patients with bladder carcinoma. As such
it will be an indispensable adjunct to cystoscopy and
other clinical means to judge the patient's condition.
Regular measurement of urinary CEA may prevent a
delay in adequate treatment.
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Addition to the proof
After submitting our paper two articles, Wahren, B., Edsmyr, F. Urology 14, 226-229, came to our attention dealing with CEA
& Zimmermann R. (1975) Cancer 36,1490-1495 and Fräser, in patients with bladder carcinoma which confirm our results.
R. A., Ravry, M J., Sugura, J. W. & Go, V. L. W., (1975) J.
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